Liver decompensation in HIV/Hepatitis B coinfection in the combination antiretroviral therapy era does not seem increased compared to hepatitis B mono‐infection
- 9 November 2018
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 39 (3) , 470-483
Abstract
Background & Aims: HIV/hepatitis B virus (HBV) coinfected subjects are thought to have faster progression to end‐stage liver disease (ESLD) than HBV mono‐infected subjects. We assessed whether this remains in the current cART‐era.Methods: Data from subjects with follow‐up completion post‐2003 were compared between HIV/HBV coinfected subjects in the Dutch HIV Monitoring database and HBV mono‐infected subjects from two centres. The primary outcomes of composite ESLD included portal hypertension, decompensated cirrhosis, hepatocellular carcinoma, liver transplantation and liver‐related mortality. Outcomes were analysed using time‐dependent cause‐specific Cox regression models adjusted for follow‐up time and relevant covariates. Subset‐analyses were done in subjects with follow‐up pre‐2003.Results: In the 1336 co‐ vs 742 mono‐infected subjects, coinfected subjects had no increased probability for ESLD compared to mono‐infected subjects (cHR 0.7 (95% CI 0.4‐1.1), but had increased probabilities for all‐cause (cHR 7.4 [4.9‐11.1]) and liver‐related mortality (cHR 3.4 [1.6‐7.5]). In the current combined cohort, treatment with tenofovir or entecavir was inversely associated with ESLD, all‐cause and liver‐related mortality (cHR 0.4 [95% CI 0.3‐0.7], cHR 0.003 [0.001‐0.01]), cHR 0.007 [0.001‐0.05]). Other predictors for ESLD were older age, being of Sub‐Sahara African descent, increased alanine aminotransferase levels and hepatitis C virus coinfection. While the probability for all‐cause mortality was increased in coinfected subjects, this rate decreased compared to pre‐2003 (HR 40.2 (95% CI: 8.7‐186.2).Conclusions: HIV/HBV coinfected patients no longer seem to be at increased risk for progression to ESLD compared to HBV mono‐infected patients, likely due to widespread use of highly effective cART with dual HBV and HIV activity.Keywords
Funding Information
- Ministerie van Volksgezondheid, Welzijn en Sport
This publication has 40 references indexed in Scilit:
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- Changes in Serum Levels of HBV DNA and Alanine Aminotransferase Determine Risk for Hepatocellular CarcinomaGastroenterology, 2011
- The Coding Causes of Death in HIV (CoDe) ProjectEpidemiology, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Tenofovir Improves the Outcome in Patients with Spontaneous Reactivation of Hepatitis B Presenting as Acute-On-Chronic Liver Failure §ΔHepatology, 2010
- Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational DatabaseJournal of Gastroenterology and Hepatology, 2007
- Hepatitis B virus and HIV coinfection: relationship of different serological patterns to survival and liver diseaseHIV Medicine, 2007
- Hepatotoxicity of antiretrovirals: Incidence, mechanisms and managementJournal of Hepatology, 2006
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Hepatitis B and C in HIV-infected patientsJournal of Hepatology, 1997